Late-Breaking Abstract Submission

Late-Breaking Abstract Submission

Late-breaking abstract submission is now closed. Thank you to everyone who submitted!

Key Dates

Abstract Submission Extended Deadline Monday, 17 April 2023, 23:59 CET
Abstract Notifications Sent in May 2023
Late-Breaking Abstract Submission Opens Thursday, 15 June 2023
Late-Breaking Abstract Submission Deadline Monday, 17 July 2023, 23:59 CET

*Note all efforts are made to send notifications by the planned date. Should there be any delays with the selection process, revised date will be posted here.


Please read the submission rules before submitting an abstract.

  • Abstracts must be submitted online via the website only.
  • Presentation Type: Abstracts can be submitted for Poster Presentations.
  • Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered. ​​

  • The same person may submit up to 5 abstracts.
  • The same person may serve as the presenting author on up to 3 abstracts.
  • Presenting authors of abstracts must be registered and paid participants.
  • Submission of an abstract acknowledges your acceptance for the abstract to be published in the official Conference publications (e.g. Conference website, programes, other promotions, etc.).
  • The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
  • All abstracts must be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a fluent English speaker, by a university scientific publications office (or other similar facilities) or by a copy editor, prior to submission.
  • Abstract submitters will be required to disclose any conflict of interests in the submission form.
  • Instructions for the preparation of presentations will be made available on the Conference website.


Before you submit your abstract, please prepare the following information:

  • Presenting author’s contact details (should be the same details as the submitting author so that the presenting author receives the correspondence about the abstract):
    Full first and family name(s)
    – Email address
    – Affiliation details: department, institution, city, state (if relevant), country
    – Phone number
  • Author and co-authors’ details
  • Abstract topic– select the abstract topic per the list of topics
  • Abstract titlelimited to 25 words in UPPER CASE
  • Abstract textlimited to 250 words including acknowledgments.
    (Please Note: word count is affected when tables are included).
  • Tables and Images – you are able to add three tables/figures per abstract. The maximum file size of each graph/image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload graphs and images in JPEG, GIF, or PNG format. Please note that images/tables may be resized to fit in the final material.
  • Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word appears the first time.
  • Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
  • Submissions may not contain patient names, hospital ID numbers, or other identifying information.
  • The submission form allows you to store your abstract as a DRAFT until the deadline. After the deadline, if not submitted, drafts will be deleted.
  • Click on the SUBMIT button at the end of the process in order to submit your abstract. Changes will not be possible to your abstract after it is submitted.
  • You will receive an abstract ID number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
  • Please contact us if you have not received confirmation that your abstract has been submitted.
  • Please do not submit multiple copies of the same abstract.


During abstract submission you will be asked to confirm that you agree to the following:

  • I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published as submitted.
  • Submission of the abstract constitutes my consent to publication (e.g. Conference website, program, other promotions, etc.)
  • As the Abstract Submitter, I warrant and represent that I am the sole owner or have the rights of all the information and content (“Content”) provided to MNF and Kenes Group (Hereafter: “The Organizers”). The publication of the abstract does not infringe any third-party rights including, but not limited to, intellectual property rights.
  • As the Abstract Submitter, I grant the Organizers a royalty-free, perpetual, irrevocable non-exclusive license to use, reproduce, publish, translate, distribute, and display the Content.
  • I understand that the presenting author must be a registered participant.
  • The Organizers reserve the right to remove from any publication and/or presentation an abstract that does not comply with the above.
  • I understand that I must select a specific Topic for my abstract allocation. Although the Committee will work hard to honor this selection, this cannot be guaranteed. The Committee reserves the right to change the Topic under which the abstract was originally submitted.
  • I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.
  • I confirm that I am not a US federal government employee or if I am a US federal government employee that the abstract was prepared as part of my official duties, in which case the statement below shall apply to the abstract:
    I am a US federal government employee and the abstract was prepared as part of my official duties and, as a result, I note that the abstract is in the public domain in the United States and I acknowledge that the abstract may be published in the United States and other countries.

All abstracts will be reviewed by the Program Committee.

Presenting authors will be notified via e-mail regarding the status of their abstracts.